New hope for stubborn Graft-Versus-Host disease: experimental drug combo enters early trial
NCT ID NCT07484113
First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times
Summary
This early-phase study tests whether the drug sarilumab can safely help adults with chronic graft-versus-host disease (cGVHD) that did not improve with the standard drug belumosudil. Ten participants will receive sarilumab alone, and researchers will monitor side effects and drug levels in the blood. The goal is to find a new treatment option for this serious complication after a stem cell transplant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CGVHD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a skin biopsy reveal how axatilimab fights scarring in chronic GVHD?
- New antibody cocktail targets stubborn liver disease after stem cell transplants
- New drug combo aims to tame transplant complication
- Arthritis drug repurposed to fight stem cell transplant complication
- New combo therapy aims to tame chronic GVHD
- New drug gecacitinib tested for tough transplant complication